These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38092258)

  • 1. Evaluation of Volumetric Response Assessment From SABR for Renal Cell Carcinoma.
    Schep DG; Vansantvoort J; Dayes I; Lukka H; Quan K; Kapoor A; Chow T; Chu W; Swaminath A
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):832-837. PubMed ID: 38092258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
    Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations.
    Correa RJM; Rodrigues GB; Chen H; Warner A; Ahmad B; Louie AV
    Am J Clin Oncol; 2018 Jun; 41(6):568-575. PubMed ID: 27635623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma.
    Reynolds HM; Parameswaran BK; Finnegan ME; Roettger D; Lau E; Kron T; Shaw M; Chander S; Siva S
    PLoS One; 2018; 13(8):e0202387. PubMed ID: 30114235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
    Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C
    BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous microwave ablation of T1a and T1b renal cell carcinoma: short-term efficacy and complications with emphasis on tumor complexity and single session treatment.
    Wells SA; Wheeler KM; Mithqal A; Patel MS; Brace CL; Schenkman NS
    Abdom Radiol (NY); 2016 Jun; 41(6):1203-11. PubMed ID: 27167230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer.
    Ali M; Koo K; Chang D; Chan P; Oon SF; Moon D; Murphy DG; Eapen R; Goad J; Lawrentschuk N; Azad AA; Chander S; Shaw M; Hardcastle N; Siva S
    Radiat Oncol; 2024 Feb; 19(1):23. PubMed ID: 38355495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of renal tumor growth rates determined by using serial volumetric CT measurements.
    Zhang J; Kang SK; Wang L; Touijer A; Hricak H
    Radiology; 2009 Jan; 250(1):137-44. PubMed ID: 19092093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
    Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK).
    Siva S; Correa RJM; Warner A; Staehler M; Ellis RJ; Ponsky L; Kaplan ID; Mahadevan A; Chu W; Gandhidasan S; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Louie AV
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):941-949. PubMed ID: 32562838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
    Siva S; Louie AV; Warner A; Muacevic A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh B; Correa RJ; Lo SS; Staehler M
    Cancer; 2018 Mar; 124(5):934-942. PubMed ID: 29266183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung volume reduction after stereotactic ablative radiation therapy of lung tumors: potential application to emphysema.
    Binkley MS; Shrager JB; Leung AN; Popat R; Trakul N; Atwood TF; Chaudhuri A; Maxim PG; Diehn M; Loo BW
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):216-23. PubMed ID: 25015205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
    Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
    Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of radiologic tumor volume and pathologic tumor volume in renal cell carcinoma (RCC).
    Choi SM; Choi DK; Kim TH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
    PLoS One; 2015; 10(3):e0122019. PubMed ID: 25799553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.
    Werner-Wasik M; Xiao Y; Pequignot E; Curran WJ; Hauck W
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):56-61. PubMed ID: 11516851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma.
    Psutka SP; Feldman AS; McDougal WS; McGovern FJ; Mueller P; Gervais DA
    Eur Urol; 2013 Mar; 63(3):486-92. PubMed ID: 22959191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma.
    Raj RK; Upadhyay R; Wang SJ; Singer EA; Dason S
    Curr Oncol; 2023 Dec; 30(12):10283-10298. PubMed ID: 38132383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Partial elective nephrectomy].
    Zungri E; Martínez L; Leal D; Lorenzo L
    Actas Urol Esp; 2012 Mar; 36(3):160-4. PubMed ID: 21955560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing radiation fibrosis from tumour recurrence after stereotactic ablative radiotherapy (SABR) for lung cancer: a quantitative analysis of CT density changes.
    Mattonen SA; Palma DA; Haasbeek CJ; Senan S; Ward AD
    Acta Oncol; 2013 Jun; 52(5):910-8. PubMed ID: 23106174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.